Subscribe to RSS
Download PDF
DOI: 10.4103/ijmpo.ijmpo_234_18
Priapism in Chronic Myeloid Leukemia: Meeting at the Crossroads and Heading in Different Directions
Financial support and sponsorship Nil.
Abstract
Chronic myeloid leukemia (CML) is the most common leukemia presenting with priapism. Due to social stigma or shyness, the real incidence of priapism in our population is difficult to estimate. Since the successful development of tyrosine kinase inhibitors, the life expectancy of CML-chronic phase (CML-CP) has been comparable to the healthy population, and the importance of priapism has further magnified. As of now, the long-term outcome and fertility issues are not very well known. We present the case of a 24-year-old previously healthy gentleman who presented with priapism and was diagnosed as CML-CP. He achieved major molecular response at 18 months. On follow-up at 2 years since the diagnosis, he offers no complaint except moderate erectile dysfunction (International Index of Erectile Function score 11), compromising his quality of life.
Publication History
Received: 28 October 2018
Accepted: 29 September 2019
Article published online:
28 June 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Hinman F. NePriapism; report of cases and a clinical study of the literature with reference to its pathogenesis and surgical treatment. Annonatal. Surg 1914; 60: 689-716
- 2 Schreibman SM, Gee TS, Grabstald H. Management of priapism in patients with chronic granulocytic leukemia. J Urol 1974; 111: 786-8
- 3 Warthin AS. Priapism persistent postmortem. Int Clin 1909; 4: 286-92
- 4 Lower WE, Christoferson LA. Priapism in leukemia. Cleveland Clin J Med 1945; 12: 133-7
- 5 Sahu KK, Mishra K, Dhibar DP, Ram T, Kumar G, Jain S. et al. Priapism as the presenting manifestation of multiple myeloma. Indian J Hematol Blood Transfus 2017; 33: 133-6
- 6 Kunst W, Sarin YK. Leukaemisches priapismus mit nervoesen pathogenese. Med Klin 1970; 3: 45-5
- 7 Jandial A, Mishra K, Rajpal S, Kakkar N, Sandal R, Lad D. et al. “Blueberry muffin spots” in an adult male successfully treated with imatinib. Indian J Hematol Blood Transfus 2019; 35: 174-5
- 8 Kopp CR, Jandial A, Mishra K, Sandal R, Malhotra P. Myasthenia gravis unmasked by imatinib. Br J Haematol 2019; 184: 321
- 9 Sinha S, Lue TF, Hellstrom WJ, McAninch JW, Tanagho EA. A refined approach to diagnosis and treatment. J Urol 1986; 136: 104-8
- 10 Chisick L, Seftel M, Kumar R. Algorithm for initial management of priapism in chronic myeloid leukaemia. Br J Haematol 2012; 159: 250-1
- 11 Jandial A, Mishra K, Sandal R, Lad D, Prakash G, Khadwal A. et al. CML patients presenting with priapism: Is there any disparity in outcome?. J Clinical Oncology 2019; 37 (15 Suppl): e18545-e18545
- 12 Sandal R, Jandial A, Mishra K, Prakash G, Khadwal A, Lad D. et al. Outcome of CML patients with de novo bleeding complications: Do they behave differently?. J Clinical Oncology 2019; 37 (Suppl. 15) e18546-e18546